Groundbreaking new capabilities for the Medtech industry

MGS acquires Technolution A/S

Technolution joins forces with MGS to provide a unique capability for the MedTech industry.

MGS acquires Technolution A/S (Denmark), the final missing link for holistic Medtech solutions, from development to production. Formteknik has already been part of the MGS Group since 2021, and now, with the integration of Technolution, expertise in R&D, consulting and regulatory management has been incorporated into the group.

Hørsholm, DENMARK – June 6, 2023 – Technolution A/S (Technolution), a fast-growing consultancy and development company within Pharma and MedTech based in Denmark, has been acquired by MGS Mfg. Group Inc. (MGS), a global medical device contract manufacturer for the healthcare and pharmaceutical markets. This partnership establishes a position unique in the industry’s value chain — providing a seamless, one-stop-shop solution from initial design to final product delivery.

The development brings together Technolution’s proven expertise in R&D, regulatory compliance, quality, and project management with MGS’s strengths in high-quality drug delivery devices, diagnostics and general MedTech technology. By combining forces, Technolution and MGS mitigate project risks for their clients, and create an approach that streamlines the supply chain and accelerates time-to-market.

Commenting on the new partnership, Technolution founder and primary shareholder Allan Spork said, “We’re very excited by this opportunity for our company. MGS has already acquired Formteknik, a provider of valuable services from the DFM/ESI to the validated upscale turn-key solution, with whom we have been working closely for more than a decade. Bringing us all together makes our offering uniquely comprehensive”.

MGS CEO Paul Manley echoed Allan’s enthusiasm, adding, “Extending our offerings into the early stages of product development takes us to the next level of medical contract manufacturing. And like Technolution, we achieve our goals with the most important factor, our employees, and nurture a culture of pioneering spirit, enthusiasm, and with a will to succeed.”

For Technolution CEO Thomas Bach Agerslev, the partnership opens new prospects for the company and its stakeholders. “Having multiple providers is inefficient and costly for Pharma and MedTech companies. That’s why they increasingly demand end-to-end solutions from a single supplier such as Technolution and MGS. For customers, this means a more integrated process, smoother collaboration through all phases, and as a result, faster time-to-market.”

Picture: Front row, from left to right: Thomas Bach Agerslev (CEO & Managing Partner, Technolution), Paul Manley (CEO & President, MGS), Allan Spork (Founder & Primary Shareholder, Technolution)